Merus NV (MRUS): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Logo korporat perusahaan merus.nl (MRUS)

Merus N.V. (MRUS) develops multispecific antibodies via the Biclonics system to combat cancer. Financial stability is supported by cash reserves and partner payments. Changes in analyst EPS growth estimates on the GURU.Markets chart reflect a trend where the 7.10 level captures the latest values. A broad spectrum of early-stage programs diversifies risk, shielding the company from potential failures in individual studies.

Merus NV (MRUS): Prakiraan wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 10.01.2026

merus.nl - rincian analitis lan metrik utama (MRUS)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Merus Corp|MRUS - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Merus|MRUS - Nilai Bisnis
- rincian nilai buku perusahaan:
Aset Bersih saben Siji Saham Merus|MRUS - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku merus.nl|MRUS - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Merus N.V.|MRUS - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Merus|MRUS - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Merus|MRUS - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Merus|Likuiditas cepet merus.nl
- data bathi resik lan rasio valuasi:
MRUS - Bathi perusahaan|Bathi mangsa ngarep Merus N.V.|MRUS - Periode bali modal bisnis|Prakiraan rega marang bathi Merus N.V.|MRUS - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Merus|MRUS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Merus|MRUS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan merus.nl|MRUS - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Merus N.V.
Analisis dhasar perusahaan:MRUS, Merus Corp
Barang utama Merus NV

The biotech sector's high sensitivity to external shocks is mitigated in Merus N.V. (MRUS) through the strategic outsourcing of antibody production, which minimizes operational risks and accelerates clinical trials. By analyzing the consensus for next year's earnings per share, an investor can view the aggregated net income forecast, allowing them to filter out market noise and assess the asset's fundamental value without overpaying.

Analisis pesaing

IMMP (Immutep Limited ADR) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Anixa Bio ANIX|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Atossa Therapeutics (ATOS)|contexttherapeutics.com - Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Mersana Therapeutics, Inc. MRSN|BCTX - Prakiraan wutah bathi saben saham kanggo taun ngarep|ESSA Pharma Inc - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep QT Imaging, Inc.